Information Provided By:
Fly News Breaks for November 16, 2015
BLUE
Nov 16, 2015 | 11:49 EDT
Cowen analyst Eric Schmidt points out that an abstract describing initial results from a NCI-led first-in-human Phase I clinical trial on an anti-BCMA CAR T in advanced multiple myeloma patients was published this morning as a late-breaking abstract for the American Society of Hematology meeting. The trial provides "clear evidence of activity" in highly refractory patients, Schmidt tells investors in a research note. He believes the problem will support increased interest in shares of bluebird bio. The analyst has an Outperform rating on the name. The stock is up 2% to $72.56 in midday trading.